View Item 

Show simple item record

뱉 synuclein genetic variability: A biomarker for dementia in Parkinson disease
dc.contributor.authorGuella, Ilaria
dc.contributor.authorEvans, Daniel M.
dc.contributor.authorSzu‐tu, Chelsea
dc.contributor.authorNosova, Ekaterina
dc.contributor.authorBortnick, Stephanie F.
dc.contributor.authorGoldman, Jennifer G.
dc.contributor.authorDalrymple‐alford, John C.
dc.contributor.authorGeurtsen, Gert J.
dc.contributor.authorLitvan, Irene
dc.contributor.authorRoss, Owen A.
dc.contributor.authorMiddleton, Lefkos T.
dc.contributor.authorParkkinen, Laura
dc.contributor.authorFarrer, Matthew J.
dc.date.accessioned2017-06-16T20:16:58Z
dc.date.available2017-08-01T14:25:48Zen
dc.date.issued2016-06
dc.identifier.citationGuella, Ilaria; Evans, Daniel M.; Szu‐tu, Chelsea ; Nosova, Ekaterina; Bortnick, Stephanie F.; Goldman, Jennifer G.; Dalrymple‐alford, John C. ; Geurtsen, Gert J.; Litvan, Irene; Ross, Owen A.; Middleton, Lefkos T.; Parkkinen, Laura; Farrer, Matthew J. (2016). "αâ synuclein genetic variability: A biomarker for dementia in Parkinson disease." Annals of Neurology 79(6): 991-999.
dc.identifier.issn0364-5134
dc.identifier.issn1531-8249
dc.identifier.urihttps://hdl.handle.net/2027.42/137619
dc.publisherWiley Periodicals, Inc.
dc.title뱉 synuclein genetic variability: A biomarker for dementia in Parkinson disease
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPsychiatry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137619/1/ana24664.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137619/2/ana24664_am.pdf
dc.identifier.doi10.1002/ana.24664
dc.identifier.sourceAnnals of Neurology
dc.identifier.citedreferenceBeyer K, Ispierto L, Latorre P, et al. Alphaâ and betaâ synuclein expression in Parkinson disease with and without dementia. J Neurol Sci 2011; 310: 112 â 117.
dc.identifier.citedreferenceGuo L, Itaya M, Takanashi M, et al. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 2005; 11: 305 â 309.
dc.identifier.citedreferencePurcell S, Neale B, Toddâ Brown K, et al. PLINK: a tool set for wholeâ genome association and populationâ based linkage analyses. Am J Hum Genet 2007; 81: 559 â 575.
dc.identifier.citedreferenceNalls MA, Pankratz N, Lill CM, et al. Largeâ scale metaâ analysis of genomeâ wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 2014; 46: 989 â 993.
dc.identifier.citedreferenceSatake W, Nakabayashi Y, Mizuta I, et al. Genomeâ wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 2009; 41: 1303 â 1307.
dc.identifier.citedreferenceMaraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alphaâ synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296: 661 â 670.
dc.identifier.citedreferenceMata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma alphaâ synuclein level. Arch Neurol 2010; 67: 1350 â 1356.
dc.identifier.citedreferenceWinkler S, Hagenah J, Lincoln S, et al. alphaâ Synuclein and Parkinson disease susceptibility. Neurology 2007; 69: 1745 â 1750.
dc.identifier.citedreferenceBras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014; 23: 6139 â 6146.
dc.identifier.citedreferenceNishioka K, Wider C, Vilarinoâ Guell C, et al. Association of alphaâ , betaâ , and gammaâ synuclein with diffuse Lewy body disease. Arch Neurol 2010; 67: 970 â 975.
dc.identifier.citedreferenceHeintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cellâ typeâ specific gene expression. Nature 2009; 459: 108 â 112.
dc.identifier.citedreferenceGymrek M, Willems T, Guilmatre A, et al. Abundant contribution of short tandem repeats to gene expression variation in humans. Nat Genet 2016; 48: 22 â 29.
dc.identifier.citedreferenceBallard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931 â 1934.
dc.identifier.citedreferenceChibaâ Falek O, Lopez GJ, Nussbaum RL. Levels of alphaâ synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 2006; 21: 1703 â 1708.
dc.identifier.citedreferenceKingsbury AE, Daniel SE, Sangha H, et al. Alteration in alphaâ synuclein mRNA expression in Parkinson’s disease. Mov Disord 2004; 19: 162 â 170.
dc.identifier.citedreferenceNeystat M, Lynch T, Przedborski S, et al. Alphaâ synuclein expression in substantia nigra and cortex in Parkinson’s disease. Mov Disord 1999; 14: 417 â 422.
dc.identifier.citedreferenceFuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alphaâ synuclein levels in the blood and brain. FASEB J 2008; 22: 1327 â 1334.
dc.identifier.citedreferenceLinnertz C, Saucier L, Ge D, et al. Genetic regulation of alphaâ synuclein mRNA expression in various human brain tissues. PLoS One 2009; 4: e7480.
dc.identifier.citedreferenceSotiriou S, Gibney G, Baxevanis AD, Nussbaum RL. A single nucleotide polymorphism in the 3’UTR of the SNCA gene encoding alphaâ synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 2009; 461: 196 â 201.
dc.identifier.citedreferenceSterling L, Walter M, Ting D, Schule B. Discovery of functional nonâ coding conserved regions in the alphaâ synuclein gene locus. F1000Res 2014; 3: 259.
dc.identifier.citedreferenceLutz MW, Saul R, Linnertz C, et al. A cytosineâ thymine (CT)â rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer’s disease and affects SNCA expression. Alzheimers Dement 2015; 11: 1133 â 1143.
dc.identifier.citedreferenceKempster PA, O’Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson’s disease: a clinicoâ pathological study. Brain 2010; 133: 1755 â 1762.
dc.identifier.citedreferenceWilliamsâ Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year followâ up of the CamPaIGN cohort. Brain 2009; 132 ( pt 11 ): 2958 â 2969.
dc.identifier.citedreferenceLevy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55: 539 â 544.
dc.identifier.citedreferenceChenâ Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 2014; 84: 594 â 607.
dc.identifier.citedreferenceThe Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629 â 635.
dc.identifier.citedreferenceGeurtsen GJ, Hoogland J, Goldman JG, et al. Parkinson’s disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis 2014; 4: 131 â 137.
dc.identifier.citedreferenceMuslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239 â 1245.
dc.identifier.citedreferenceLitvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PDâ MCI. Mov Disord 2011; 26: 1814 â 1824.
dc.identifier.citedreferenceAarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8â year prospective study. Arch Neurol 2003; 60: 387 â 392.
dc.identifier.citedreferenceHely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837 â 844.
dc.identifier.citedreferenceRosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170 â 1176.
dc.identifier.citedreferenceEmre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689 â 1707; quiz 837.
dc.identifier.citedreferenceLippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812 â 819.
dc.identifier.citedreferenceMcKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9 ( 3 suppl ): 417 â 423.
dc.identifier.citedreferenceHarding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355 â 363.
dc.identifier.citedreferenceJellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinicoâ pathological study. J Neural Transm Suppl 2007;( 72 ): 91 â 104.
dc.identifier.citedreferenceHowlett DR, Whitfield D, Johnson M, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 2015; 25: 401 â 408.
dc.identifier.citedreferenceRuffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol 2015; DOI: 10.1111/nan.12294.
dc.identifier.citedreferencePoulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord 2012; 27: 831 â 842.
dc.identifier.citedreferenceRajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonismâ a prospective study. Can J Neurol Sci 1991; 18: 275 â 278.
dc.identifier.citedreferenceGelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33 â 39.
dc.identifier.citedreferenceHughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicoâ pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181 â 184.
dc.identifier.citedreferenceMcKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863 â 1872.
dc.identifier.citedreferenceDalrympleâ Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: wellâ suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717 â 1725.
dc.identifier.citedreferenceHu MT, Szewczykâ Krolikowski K, Tomlinson P, et al. Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 2014; 29: 351 â 359.
dc.identifier.citedreferenceJohnson J, Hague SM, Hanson M, et al. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004; 63: 554 â 556.
dc.identifier.citedreferenceSteele JC, Guella I, Szuâ Tu C, et al. Defining neurodegeneration on Guam by targeted genomic sequencing. Ann Neurol 2015; 77: 458 â 468.
dc.identifier.citedreferenceWang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from highâ throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
dc.identifier.citedreferenceBarrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263 â 265.
dc.identifier.citedreferenceLi H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078 â 2079.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ana24664.pdf
Size:
434.2KB
Format:
PDF
View/Open
Name:
ana24664_am.pdf
Size:
3.510MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.